Interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials

Journal of Viral Hepatitis

Volumn 15, Issue 2, 2008, Pages 79-88

  Fabrizi, F ^a,b   Dixit, V ^c   Messa, P ^b   Martin, P ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dialysis; Hepatitis C; Interferon; Meta analysis; Sustained virological response

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

AGE DISTRIBUTION; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; BONE MARROW DEPRESSION; BONE PAIN; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DEHYDRATION; DEPRESSION; DIALYSIS; DIARRHEA; DROP OUT RATE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; GRAFT REJECTION; HEART FAILURE; HEMATOLOGIC DISEASE; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER TOXICITY; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; PANCREATITIS; PARAMETER; PATIENT COMPLIANCE; PERICARDITIS; PNEUMONIA; PRIORITY JOURNAL; PUBLISHING; SEIZURE; SENSITIVITY ANALYSIS; SEPSIS; SEPTICEMIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; SUSTAINED VIROLOGICAL RESPONSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; KIDNEY FAILURE, CHRONIC; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 37649006377     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00907.x     Document Type: Article

References (68)

1. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005 18 : 52 61.
2. Fissell RB, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis C prevalence and seroconversion in HD units from three continents. Kidney Int 2004 65 : 2335 2342.
3. Hmaied F, Ben Mamou M, Saune-Sandres K et al. Hepatitis C virus infection among dialysis patients in Tunisia. Incidence and molecular evidence for nosocomial transmission. J Med Virol 2006 72 : 185 191.
4. Chattopadhyay S, Rao S, Das BC, Singh NP, Kar P. Prevalence of transfusion-transmitted virus infection in patients on maintenance hemodialysis from New Delhi, India. Hemodial Int 2005 9 : 362 366.
5. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000 11 : 1896 1902.
6. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007 18 : 1584 1593.
7. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal replacement therapy, and outcome after kidney transplantation. Transplantation 2004 78 : 745 750.
8. Morales JM, Dominguez-Gil B, Sanz-Gajardo D, Fernandez J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004 19 : S72 S76.
9. Stehman-Breen CO, Psaty BM, Emerson S et al. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients. Transplantation 1997 64 : 281 286.
10. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat 2001 8 : 287 292.
11. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004 36 : 1831 1834.
12. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006 13 : 316 321.
13. Rendina M, Schena A, Castellaneta NM et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007 46 : 768 774.
14. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003 18 : 1071 1081.
15. Russo MW, Goldsweig C, Jacobson IM, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003 98 : 1610 1615.
16. Poynard T, Conn HO. The retrieval of randomised clinical trials in liver diseases from the medical literature: A comparison of MEDLARS and manual methods. Control Clin Trials 1985 6 : 271 279.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 188.
18. Petitti DB. Approaches to heterogeneity in meta-analysis. Statist Med 2001 20 : 3625 3633.
19. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistencies in meta-analysis. Br Med J 2003 327 : 557 560.
20. Begg CB, Mazumadar M. Operating characteritics of a rank correlation test for publication bias. Biometrics 1994 50 : 1088 1098.
21. Egger M, Smith DG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997 315 : 629 634.
22. Koenig P, Vogel W, Umlauft F et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994 45 : 1507 1509.
23. Pol S, Thiers V, Carnot F et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995 47 : 1412 1418.
24. Raptopoulou-Gigi M, Spaia S, Garifallos A et al. Interferon-alpha2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995 10 : 1834 1837.
25. Fernandez JL, Rendo P, del Pino N. Nephrologists group for the study of HCV infection and Viola L. A double-blind controlled trial of recombinant inteferon-alpha2b in hamodialysis patients with chronic hepatitis C virus infection and abnormal aminotrasferase levels. J Viral Hepat 1997 4 : 113 119.
26. Chan TM, Wu PC, Lau JYN, Lok ASF, Lai CL, Cheng IKP. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997 12 : 1414 1419.
27. Uchihara M, Izumi N, Sakai Y et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron 1998 80 : 51 56.
28. Benci A, Caremani M, Menchetti D, Sasdelli M, Giusti PB. Low-dose leucocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Curr Med Res 1998 14 : 141 144.
29. Boran M, Cetin S. The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy. Nephron 1999 82 : 22 26.
30. Campistol JM, Esforzado N, Martinez J et al. Efficacy and tolerance of interferon-alpha2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Nephrol Dial Transplant 1999 14 : 2704 2709.
31. Hanrotel C, Toupance O, Lavaud S et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001 88 : 120 126.
32. Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001 21 : 435 440.
33. Casanovas-Taltavull T, Baliellas C, Benasco C et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001 96 : 1170 1177.
34. Degos F, Pol S, Chaix ML et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001 16 : 1017 1023.
35. Espinosa M, Rodriguez M, Martin-Malo A et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001 55 : 220 226.
36. Sporea I, Golea O, Ursu C et al. Effect of alpha 2b interferon treatment in hemodialyzed patients with chronic hepatitis C. Rom J Gastroenterol 2001 10 : 285 288.
37. Kamar N, Toupance O, Buchler M et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sutained after renal transplantation. J Am Soc Nephrol 2003 14 : 2092 2098.
38. Ozdemir FN, Akcay A, Sezer S et al. A six-year follow-up after interferon-alpha monotherapy for chronic hepatitis C infection in hemodialysis patients. Ren Fail 2004 26 : 583 588.
39. Mahmoud IM, Sobh MA, El-Habashi AF et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005 100 : c133 c139.
40. Rivera M, Gentil MA, Sayago M et al. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc 2005 37 : 1424 1425.
41. Rocha CM, Perez RM, Ferreira AP et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006 26 : 305 310.
42. Buargub M, El Huni S, Tagdi M. Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. Saudi J Kidney Dis Transplant 2006 17 : 338 343.
43. Chow WC, Tien SL, Tan CK, Lui HF, Vathsala A, Ng HS. Treatment of chronic hepatitis C in patients with end-stage renal disease and hemophilia- the Singapore experience. Intervirology 2006 49 : 107 111.
44. Yildirim B, Durak H, Ozaras R et al. Liver steatosis in hepatitis C positive hemodialysis patients and factors affecting IFN-2a treatment. Scand J Gastroenterol 2006 41 : 1235 1241.
45. Grgurevic I, Vince A, Buljevac M et al. Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin Pract 2006 103 : c8 c11.
46. Sporea I, Popescu A, Sirli R et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006 12 : 4191 4194.
47. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006 21 : 437 443.
48. Covic A, Maftei ID, Mardare NGI et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006 19 : 794 801.
49. Kokoglu OF, Ucmak H, Hosoglu S et al. Efficacy and tolerability of pegylated -interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006 21 : 575 580.
50. Pol S, Thiers V, Carnot F et al. Effectiveness and tolerance of interferon alpha-2b in the treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1996 11 : 58 61.
51. Izopet J, Rostaing L, Moussion F et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997 176 : 1614 1617.
52. Huraib S, Tanimu D, Romeh SA et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999 34 : 55 60.
53. Gonzalez-Roncero F, Gentil MA, Valdivia MA et al. Outcome of kidney transplant in chronic hepatitis C virus patients: effect of pretransplantation interferon-alpha2b monotherapy. Transplant Proc 2003 35 : 1745 1747.
54. Annichiarico BE, Siciliano M. Pegylated interferon-alpha2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther 2004 20 : 123 127. [letter]
55. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005 20 : 991 993.
56. Chan TM, Ho SKN, Tang CSO et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology 2006 10 : 1440 1444.
57. Mukherjee S, Gilroy RK, McCashland TM, Schafer DF. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: A prospective cohort study. Transplant Proc 2003 35 : 1478 1479.
58. Engel M, Malta FM, Gomes MS et al. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Soutwest Parana State, Brazil. BMC Public Health 2007 7 : 50 56.
59. Fabrizi F, Poordad F, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002 36 : 3 10.
60. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001 8 : 48 62.
61. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared wih interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis: a randomised trial. Lancet 2001 358 : 958 965.
62. Fried MW, Shiffmann ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
63. Hadziyannis SJ, Sette H, Morgan TR et al. Pegasys International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration of ribavirin dose. Ann Intern Med 2004 140 : 346 355.
64. Martin P, Carter D, Fabrizi F et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000 15 : 1479 1484.
65. Rostaing L, Chatelut E, Payen JL et al. Pharmacokinetic of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998 9 : 2344 2348.
66. Badalamenti S, Catania A, Lunghi G et al. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus positive patients: only coincidental phenomena? Am J Kidney Dis 2003 42 : 143 150.
67. Rampino T, Arbustini E, Gregorini M et al. Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. Kidney Int 1999 56 : 2286 2291.
68. Reddy KR, Hoofnagle JH, Tong MJ et al. Consensus Interferon Study Group. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999 30 : 787 793.